Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Spinal Muscular Atrophy Market?

In the last few years, the spinal muscular atrophy market has seen significant growth. It is projected to expand from $3.53 billion in 2024 to $4.01 billion in 2025, with a compound annual growth rate (CAGR) of 13.5%. The surge during the past period has been driven by factors such as escalated diagnosis and early detection, rising incidences of uncommon genetic diseases, enhanced healthcare infrastructure, government and regulatory backing, as well as an upswing in unresolved healthcare requirements.

What Growth Rate Is Forecasted for the Spinal Muscular Atrophy Market by 2029?

There is anticipated rapid expansion in the spinal muscular atrophy market in the ensuing years. It is projected to reach $6.59 billion in 2029, with a compound annual growth rate (CAGR) of 13.2%. Factors contributing to this growth in the forecast period include enhanced awareness and diagnosis, wider access to treatment, an increase in healthcare investments that target rare diseases, a conducive regulatory environment, and escalating healthcare expenditure. Noteworthy trends in the anticipated period comprise breakthroughs in oral therapies, the utilization of gene therapy, advances in technologies for drug delivery systems, the use of artificial intelligence in the development of SMA treatments, and cutting-edge gene editing technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

Which Key Companies Are Shaping the Future of the Spinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.

Which Factors Are Driving Demand in the Spinal Muscular Atrophy Industry?

The growth of the spinal muscular atrophy market is anticipated to be accelerated by the escalating rates of rare genetic disorders. These genetic disorders, which affect a small portion of the overall population, are born out of mutated genes and often lead to intense, chronic health issues. Upgraded diagnostic technologies, heightened public consciousness, and enhanced access to genetic testing have all contributed to the increase in recognized and reported cases of rare genetic disorders. Spinal muscular atrophy (SMA), a peculiar genetic disorder, epitomizes the difficulties and possibilities of comprehending inherited maladies, highlighting the urgency of progressing genetic condition-related research. For example, in July 2023, a study by the Office for National Statistics, a governmental department in the UK, made it known that genetic testing of SMN1 has paved the way for exact epidemiological studies. It confirmed that SMA is found in 1 in 10,000 to 20,000 live births, with over 95% of patients affected being homozygous for SMN1 deletion. Consequently, the increasing rates of rare genetic disorders are set to stimulate the expansion of the spinal muscular atrophy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

How Is the Spinal Muscular Atrophy Market Segmented by Several Divisions?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

What are the Emerging Market Trends Driving the Growth of the Spinal Muscular Atrophy Industry?

Leading firms in the spinal muscular atrophy market are advancing their product offerings by developing unique solutions like dry syrup. This innovation aims to aid medication compliance and simplify administration for pediatric patients and other groups who experience difficulty swallowing. Dry syrup, a medication in powdered form, is mixed with water prior to consumption and is usually prescribed for children and patients who struggle with intaking tablets or capsules. Chugai Pharmaceutical Co., Ltd., a pharmaceutical organization based in Japan, reported in September 2024 that it had received regulatory approval from the nation’s Ministry of Health, Labour and Welfare for widened usage of their drug, Evrysdi (risdiplam). The approval allows Evrysdi to be used in pre-symptomatic spinal muscular atrophy (SMA) and expands dosing to infants younger than two months. This development is significant as it allows treatment to start before symptoms manifest, potentially improving therapeutic results in affected infants. The decision was backed by the RAINBOWFISH study’s findings, which evaluated the safety and efficacy of Evrysdi in infants diagnosed with SMA but not yet showing symptoms. The results demonstrated that infants treated with the drug reached developmental milestones including unsupported sitting and better motor skills within 12 months, pointing to the drug’s capacity to alter the course of the disease when administered promptly.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Regions Are Driving Growth in the Spinal Muscular Atrophy Market?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965

This Report Delivers Insight On:

1. How big is the spinal muscular atrophy market, and how is it changing globally?

2. Who are the major companies in the spinal muscular atrophy market, and how are they performing?

3. What are the key opportunities and risks in the spinal muscular atrophy market right now?

4. Which products or customer segments are growing the most in the spinal muscular atrophy market?

5. What factors are helping or slowing down the growth of the spinal muscular atrophy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model